References
- Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421–6.
- Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?Arthritis Rheum. 2004;50(3):689–98.
- Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive hemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients.Rheumatology. 2001;40(11):1285–92.
- Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128(2):275–8.
- Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106(4):561–6.
- Grom AA. Macrophage activation syndrome. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: WB Saunders; 2011. p. 674–81.
- Mizushima Y, Hamano T, Yokoyama K. Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann Rheum Dis. 1982;41(3):263–7.
- Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. P-glycoprotein in autoimmune diseases. Autoimmun Rev. 2004; 3(3):188–92.
- Behrens EM. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell?Autoimmun Rev. 2008;7(4):305–8.
- Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.
- Pak CC, Fidler IJ. Liposomal delivery of biological response modifiers to macrophages. Biotherapy. 1991;3(1):55–64.
- Nishiwaki S, Nakayama T, Murata M, Nishida T, Sugimoto K, Saito S, et al. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. Int J Hematol. 2012;95(4): 428–33.